171 related articles for article (PubMed ID: 35232925)
1. Update on immunosuppressive strategies in intestinal transplantation.
Merola J; Shamim A; Weiner J
Curr Opin Organ Transplant; 2022 Apr; 27(2):119-125. PubMed ID: 35232925
[TBL] [Abstract][Full Text] [Related]
2. Updates in induction immunosuppression regimens for intestinal transplantation.
Paulo Guzman J; Maklad M; Osman M; Elsherif A; Fujiki M
Hum Immunol; 2024 May; 85(3):110800. PubMed ID: 38599892
[TBL] [Abstract][Full Text] [Related]
3. Evolutionary experience with immunosuppression in pediatric intestinal transplantation.
Bond GJ; Mazariegos GV; Sindhi R; Abu-Elmagd KM; Reyes J
J Pediatr Surg; 2005 Jan; 40(1):274-9; discussion 279-80. PubMed ID: 15868597
[TBL] [Abstract][Full Text] [Related]
4. Association of Alemtuzumab Induction With a Significantly Lower Incidence of GVHD Following Intestinal Transplantation: Results of 445 Consecutive Cases From a Single Center.
Vianna R; Farag A; Gaynor JJ; Selvaggi G; Tekin A; Garcia J; Pierce C; Beduschi T
Transplantation; 2020 Oct; 104(10):2179-2188. PubMed ID: 31929428
[TBL] [Abstract][Full Text] [Related]
5. Experimental short-term immunosuppression after bowel transplantation and donor-specific bone marrow infusion.
Harmon JV; Gruessner AC; Nakhleh RE; Zhang K; Gruessner RW
Arch Surg; 2001 Jul; 136(7):817-21. PubMed ID: 11448397
[TBL] [Abstract][Full Text] [Related]
6. Challenges with Intestine and Multivisceral Re-Transplantation: Importance of Timing of Re-Transplantation and Optimal Immunosuppression.
Kubal CA; Pennington C; Fridell J; Ekser B; Muhaylov P; Mangus R
Ann Transplant; 2018 Feb; 23():98-104. PubMed ID: 29402878
[TBL] [Abstract][Full Text] [Related]
7. Tolerogenic protocols for intestinal transplantation.
Pirenne J; Kawai M
Transpl Immunol; 2004; 13(2):131-7. PubMed ID: 15380543
[TBL] [Abstract][Full Text] [Related]
8. Induction regimens and post-transplantation lymphoproliferative disorder after pediatric intestinal transplantation: Single-center experience.
Devine K; Ranganathan S; Mazariegos G; Bond G; Soltys K; Ganoza A; Sun Q; Sindhi R
Pediatr Transplant; 2020 Aug; 24(5):e13723. PubMed ID: 32424963
[TBL] [Abstract][Full Text] [Related]
9. Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance.
Abu-Elmagd KM; Costa G; Bond GJ; Wu T; Murase N; Zeevi A; Simmons R; Soltys K; Sindhi R; Stein W; Demetris A; Mazariegos G
Transpl Int; 2009 Jan; 22(1):96-109. PubMed ID: 18954362
[TBL] [Abstract][Full Text] [Related]
10. Clinical intestinal transplantation: new perspectives and immunologic considerations.
Abu-Elmagd K; Reyes J; Todo S; Rao A; Lee R; Irish W; Furukawa H; Bueno J; McMichael J; Fawzy AT; Murase N; Demetris J; Rakela J; Fung JJ; Starzl TE
J Am Coll Surg; 1998 May; 186(5):512-25; discussion 525-7. PubMed ID: 9583691
[TBL] [Abstract][Full Text] [Related]
11. Complete freedom from rejection after intestinal transplantation using a new tolerogenic protocol combined with low immunosuppression.
Pirenne J; Koshiba T; Geboes K; Emonds MP; Ferdinande P; Hiele M; Nevens F; Waer M
Transplantation; 2002 Mar; 73(6):966-8. PubMed ID: 11923701
[TBL] [Abstract][Full Text] [Related]
12. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
13. Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration.
Kueckelhaus M; Fischer S; Seyda M; Bueno EM; Aycart MA; Alhefzi M; ElKhal A; Pomahac B; Tullius SG
Transpl Int; 2016 Jun; 29(6):655-62. PubMed ID: 26265179
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressant strategies for intestinal transplantation: a review of a tolerogenic regimen.
Flynn B; Park BK; Bond G; McGhee W; Mazariegos G; Sindhi R; Reyes J; Abu-Elmagd K
Prog Transplant; 2005 Mar; 15(1):60-4. PubMed ID: 15839373
[TBL] [Abstract][Full Text] [Related]
15. Current status of graft-versus-host disease after intestinal transplantation.
Ganoza A; Mazariegos GV; Khanna A
Curr Opin Organ Transplant; 2019 Apr; 24(2):199-206. PubMed ID: 30762668
[TBL] [Abstract][Full Text] [Related]
16. Late graft loss after intestinal transplantation.
Kaenkumchorn T; Wendel D; Pacheco MC; Horslen SP
Curr Opin Organ Transplant; 2021 Apr; 26(2):220-228. PubMed ID: 33528223
[TBL] [Abstract][Full Text] [Related]
17. Intestinal transplantation: evolution in immunosuppression protocols.
Pirenne J; Kawai M
Curr Opin Organ Transplant; 2009 Jun; 14(3):250-5. PubMed ID: 19373085
[TBL] [Abstract][Full Text] [Related]
18. Novel immunosuppressive strategies for composite tissue allografts.
Gupta A; Kumer S; Kaplan B
Curr Opin Organ Transplant; 2014 Dec; 19(6):552-7. PubMed ID: 25333828
[TBL] [Abstract][Full Text] [Related]
19. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants.
Borie DC; O'Shea JJ; Changelian PS
Trends Mol Med; 2004 Nov; 10(11):532-41. PubMed ID: 15519279
[TBL] [Abstract][Full Text] [Related]
20. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
Hale G; Zhang MJ; Bunjes D; Prentice HG; Spence D; Horowitz MM; Barrett AJ; Waldmann H
Blood; 1998 Dec; 92(12):4581-90. PubMed ID: 9845524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
